Clinical Trial

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-23.
Status change: Enrolling by Invitation → Recruiting 2025-08-07
Trial Details
NCT Number NCT07093476
Lead Sponsor Celltrion
Conditions T2DM, Diabete Type 2, DM
Enrollment 171 participants
Start Date 2025-07-18
Primary Completion 2026-12 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-08-11